patient

Therapy for acute myeloid leukemia in older and unfit adults

Original Publication Date
Article Source
External Web Content
TITLE Azacitidine and venetoclax in previously untreated acute myeloid leukemia. AUTHORS DiNardo CD, Jonas BA, Pullarkat V, et al. JOURNAL The New England Journal of Medicine. 2020;383:617-629. doi: 10.1056/NEJMoa2012971. The therapy of acute myeloid leukemia (AML) has…

Allogeneic Hematopoietic Cell Transplantation for the Treatment of Severe Aplastic Anemia: Evidence-Based Guidelines From the American Society for Transplantation and Cellular Therapy

Original Publication Date
Article Source
External Web Content
Allogeneic hematopoietic cell transplantation (HCT) is a potentially curative treatment for severe aplastic anemia (SAA). Existing guidance about HCT in SAA is primarily derived from expert reviews, registry data and societal guidelines; however, transplant-specific guidelines…

Hassan Alkhateeb, MD  

Institution
Mayo Clinic - Rochester
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Chronic Lymphocytic Leukemia (CLL)
Chronic Myelomonocytic Leukaemia (CMML)
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Pediatric

Alejandro Marinos Velarde, MD 

Institution
UT Southwestern Medical Center
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
About
Alejandro Marinos Velarde, M.D., is an Assistant Professor in the Department of Internal Medicine at UT Southwestern Medical Center. He specializes in allogeneic stem cell transplant and acute myeloid leukemia. Dr. Marinos Velarde earned his medical degree at the Facultad de Medicina Alberto Hurtado, Universidad Peruana Cayetano Heredia in Lima, Peru. He completed a residency in internal medicine at Beaumont Hospital in Royal Oak, Michigan; a fellowship in hematology and oncology at the Baylor College of Medicine in Houston; and a fellowship in stem cell transplant and cellular therapy at MD

Gloria Gerber, MD  

Institution
Johns Hopkins University
Physician Status
accepting new patients
Primary Disease Area of Focus
Paroxysmal Nocturnal Hemoglobinuria (PNH)
About
Dr. Gloria F. Gerber is an Assistant Professor of Medicine at Johns Hopkins University in the Division of Hematology. She received her undergraduate degree in Biology with High Honors from Dartmouth College and M.D. from Rutgers Robert Wood Johnson Medical School. She completed her Internal Medicine Residency at New York Presbyterian Weill Cornell Medical Center and Fellowship in Hematology at Johns Hopkins. Dr. Gerber specializes in the treatment of adult patients with non-malignant hematologic diseases namely coagulation disorders and thromboembolic diseases as well as hematologic diseases

Afaf Osman, MD

Institution
University of Utah School of Medicine
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)

Pankit Vachhani, MD

Institution
University of Alabama Birmingham
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
About
Dr. Pankit Vachhani is an Assistant Professor of Medicine at the University of Alabama at Birmingham and Associate Scientist of Experimental Therapeutics. He graduated from Weill Cornell Medical College in Qatar in 2012 and on to complete his internal medicine residency at Virginia Commonwealth University, followed by a fellowship in hematology/oncology at Roswell Park Comprehensive Cancer Center in Buffalo, NY. Clinical Interests & Research: At UAB, he is involved in multiple clinical trials as a principal investigator. He leads the Leukemia/BMT working group. His primary research interest is

Risk prediction for clonal cytopenia: multicenter real-world evidence

Original Publication Date
Article Source
External Web Content
Key Points A 3-parameter CCRS model was devised specifically for patients diagnosed with clonal cytopenia. The CCRS offers precise CCUS risk assessment for patient management and clinical trial eligibility. Abstract Clonal cytopenia of undetermined significance (CCUS) represents…
Subscribe to patient

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.